Drugs / CVD 1208S
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01531530 | Jul 2011 → Sep 2012 | shigellosis | University of Maryland, Baltimore | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT00866242 | Jan → Feb 2010 | shigellosis | University of Maryland, Baltimore | Terminated | No outcome recorded |
| Phase 2 | NCT00866476 | Jan → Feb 2010 | shigellosis | University of Maryland, Baltimore | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CVD 1208S | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01531530 ↗ |
| Modality | Vaccine | “CVD 1208S (a live, attenuated, oral vaccine)” NCT00866242 ↗ |
| Route | Oral | “a live, attenuated, oral vaccine” NCT00866242 ↗ |